MX2018000697A - Peptidos anti-inflamatorios y usos de los mismos. - Google Patents
Peptidos anti-inflamatorios y usos de los mismos.Info
- Publication number
- MX2018000697A MX2018000697A MX2018000697A MX2018000697A MX2018000697A MX 2018000697 A MX2018000697 A MX 2018000697A MX 2018000697 A MX2018000697 A MX 2018000697A MX 2018000697 A MX2018000697 A MX 2018000697A MX 2018000697 A MX2018000697 A MX 2018000697A
- Authority
- MX
- Mexico
- Prior art keywords
- region
- inflammatory
- amino acid
- terminal amino
- methionine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Birds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Un péptido anti-inflamatorio comprende un fragmento anti-inflamatorio de una proteína seleccionada a partir de las SEQ ID NOs: 1 a 16, en donde el fragmento anti-inflamatorio es de 7 a 37 aminoácidos de longitud y tiene una carga de entre -9 y +3; en donde el aminoácido C-terminal no es cisteína (C) o metionina (M), y el aminoácido N-terminal no es cisteína (C), histidina (H), prolina (P) o treonina (T). El fragmento anti- inflamatorio no contiene cisteína (C). El fragmento anti-inflamatorio es a partir de una región de las proteínas de las SEQ ID NOs: 1 a 16, en donde esta región se caracteriza porque es de 17 a 109 aminoácidos de longitud y porque tiene una carga de entre -6 y +4, en donde el aminoácido C-terminal de la región no es ácido aspártico (D), fenilalanina (F), metionina (M) o triptófano (W), y el aminoácido N-terminal de la región no es ácido aspártico (D), histidina (H), metionina (M), prolina (P) o triptófano (W). Los ejemplos de los péptidos se proporcionan en las SEQ ID NOs: 71 a 221.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15177013.8A EP3118215A1 (en) | 2015-07-16 | 2015-07-16 | Anti-inflammatory peptides, and uses thereof |
| EP15177017.9A EP3118216A1 (en) | 2015-07-16 | 2015-07-16 | Cellular growth and proliferation promoting peptides, and uses thereof |
| PCT/EP2016/067090 WO2017009484A1 (en) | 2015-07-16 | 2016-07-18 | Anti-inflammatory peptides, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018000697A true MX2018000697A (es) | 2018-08-15 |
Family
ID=56686757
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000697A MX2018000697A (es) | 2015-07-16 | 2016-07-18 | Peptidos anti-inflamatorios y usos de los mismos. |
| MX2020010806A MX2020010806A (es) | 2015-07-16 | 2018-01-16 | Peptidos anti-inflamatorios y usos de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010806A MX2020010806A (es) | 2015-07-16 | 2018-01-16 | Peptidos anti-inflamatorios y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10463591B2 (es) |
| EP (3) | EP3322430B1 (es) |
| JP (3) | JP2018523703A (es) |
| KR (3) | KR102576571B1 (es) |
| CN (2) | CN108348568B (es) |
| AU (2) | AU2016293129B2 (es) |
| BR (1) | BR112018000660A2 (es) |
| CA (1) | CA2992378A1 (es) |
| DK (1) | DK3322430T3 (es) |
| ES (1) | ES2806989T3 (es) |
| MX (2) | MX2018000697A (es) |
| WO (1) | WO2017009484A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020504714A (ja) * | 2016-12-05 | 2020-02-13 | ニューリタス リミテッド | ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物 |
| KR102354916B1 (ko) * | 2020-02-11 | 2022-01-26 | 주식회사 쓰리빅스 | 신규 펩타이드 3ps_i014 및 이의 용도 |
| FR3114744B1 (fr) | 2020-10-02 | 2024-01-05 | Basf Beauty Care Solutions France Sas | Nouvelle utilisation d’un peptide pour améliorer le confort de la peau et/ou des muqueuses et/ou l’apparence des phanères |
| WO2022131820A1 (ko) * | 2020-12-16 | 2022-06-23 | 아주대학교산학협력단 | 아토피 피부염 예방 또는 치료용 항염증 펩타이드 |
| CN114478702B (zh) * | 2022-04-06 | 2023-12-12 | 中南林业科技大学 | 一种米糠来源短肽及其在治疗皮肤损伤中的应用 |
| CN116375828B (zh) * | 2022-09-08 | 2024-06-04 | 浙江大学 | 一种具有抗菌活性的抗菌肽kta及其应用 |
| CN116253782B (zh) * | 2022-09-08 | 2024-06-04 | 浙江大学 | 一种广谱抗菌肽ktr及其应用 |
| FR3141066A1 (fr) | 2022-10-24 | 2024-04-26 | Basf Beauty Care Solutions France Sas | Nouvelle utilisation d’un peptide pour améliorer la matrice extracellulaire du derme de la peau et/ou des muqueuses |
| CN116491631B (zh) * | 2023-05-26 | 2024-06-25 | 青岛农业大学 | 一种预制菜红烧肉及其制备方法 |
| CN117736271A (zh) * | 2023-06-29 | 2024-03-22 | 长沙理工大学 | 一种米渣蛋白源免疫活性肽及其应用 |
| CN117986337A (zh) * | 2024-02-02 | 2024-05-07 | 北京川晋生物科技有限公司 | 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| AU1422492A (en) | 1991-03-07 | 1992-10-06 | Novo Nordisk A/S | Pea protein hydrolyzate, method for production thereof and use thereof |
| US5516642A (en) | 1992-11-16 | 1996-05-14 | Bristol-Myers Squibb Company | Polypeptides derived from major histocompatibility complex Class I antigen |
| JP2673659B2 (ja) | 1994-02-11 | 1997-11-05 | 株式会社ホーネンコーポレーション | ペプチド |
| US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| IT1313572B1 (it) | 1999-07-27 | 2002-09-09 | Enichem Spa | Procedimento per la preparazione di epossidi. |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| JP2001335596A (ja) | 2000-05-24 | 2001-12-04 | Kenji Sakamoto | 新規ペプチド及びその医薬用途 |
| EP1415137A4 (en) | 2001-04-17 | 2007-04-25 | Ista S P A | METHODS FOR MASS SPECTROMETRY DETECTION AND QUANTIFICATION OF SPECIFIC TARGET PROTEINS IN COMPLEX BIOLOGICAL SAMPLES |
| AU2003290582A1 (en) * | 2002-11-04 | 2004-06-07 | Florida State University Research Foundation | NUCLEIC ACID AND ALLERGENIC POLYPEPTIDES ENCODED THEREBY IN CASHEW NUTS (Anacardium occidentale) |
| SE0300795D0 (sv) | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
| CA2526428A1 (en) | 2003-05-23 | 2005-03-17 | Pestka Biomedical Laboratories, Inc. | Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections |
| KR101045658B1 (ko) | 2003-11-17 | 2011-07-01 | 쎄데르마 | 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물 |
| US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| EP1896496B1 (en) | 2005-06-29 | 2012-01-11 | Hadasit Medical Research Services & Development Ltd. | Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes |
| US8105572B2 (en) | 2007-05-18 | 2012-01-31 | New York University | Method of treating tuberculosis with interferons |
| KR100759495B1 (ko) | 2006-02-17 | 2007-09-18 | 재단법인서울대학교산학협력재단 | 친수성 생리활성 펩타이드와 소수성 물질을 포함한자기조립 나노구조체 |
| JP5645360B2 (ja) | 2006-04-21 | 2014-12-24 | 株式会社明治 | ジペプチドを有効成分として含有する組成物 |
| US9034402B2 (en) | 2007-04-16 | 2015-05-19 | Solae, Llc | Protein hydrolysate compositions having improved sensory characteristics and physical properties |
| EP2698433A1 (en) | 2007-06-06 | 2014-02-19 | Monsanto Technology LLC | Genes and uses for plant enhancement |
| CA2697413A1 (en) * | 2007-08-24 | 2009-03-05 | Mylexa Pty Limited | Modulators of hypersensitivity reactions |
| EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| WO2011122937A1 (en) | 2010-03-29 | 2011-10-06 | N.V. Nutricia | Pea protein peptides with anti helicobacter pylori activity |
| ES2397890B1 (es) | 2011-03-25 | 2014-02-07 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas. |
| EP2793605A1 (en) * | 2011-12-21 | 2014-10-29 | Laboratorios Ordesa, S.L | Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity |
| CA2883569A1 (en) | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| ES2676436T3 (es) * | 2013-02-19 | 2018-07-19 | Danone, S.A. | Péptidos funcionales para trastornos de obesidad |
| US9814670B2 (en) | 2014-12-04 | 2017-11-14 | Mary Kay Inc. | Cosmetic compositions |
| US20170183386A1 (en) | 2015-07-16 | 2017-06-29 | Nuritas Limited | Peptides, and uses thereof |
-
2016
- 2016-07-18 BR BR112018000660-2A patent/BR112018000660A2/pt active Search and Examination
- 2016-07-18 JP JP2018521713A patent/JP2018523703A/ja active Pending
- 2016-07-18 WO PCT/EP2016/067090 patent/WO2017009484A1/en active Application Filing
- 2016-07-18 KR KR1020217030710A patent/KR102576571B1/ko active IP Right Grant
- 2016-07-18 EP EP16751491.8A patent/EP3322430B1/en active Active
- 2016-07-18 MX MX2018000697A patent/MX2018000697A/es active IP Right Grant
- 2016-07-18 AU AU2016293129A patent/AU2016293129B2/en active Active
- 2016-07-18 CN CN201680051932.6A patent/CN108348568B/zh active Active
- 2016-07-18 EP EP20165063.7A patent/EP3747425A1/en not_active Withdrawn
- 2016-07-18 ES ES16751491T patent/ES2806989T3/es active Active
- 2016-07-18 KR KR1020187004160A patent/KR102307260B1/ko active IP Right Grant
- 2016-07-18 EP EP21178569.6A patent/EP3954700A1/en active Pending
- 2016-07-18 CN CN202111590603.8A patent/CN114835784A/zh active Pending
- 2016-07-18 CA CA2992378A patent/CA2992378A1/en active Pending
- 2016-07-18 US US15/744,304 patent/US10463591B2/en active Active
- 2016-07-18 KR KR1020237030244A patent/KR20230132623A/ko active Application Filing
- 2016-07-18 DK DK16751491.8T patent/DK3322430T3/da active
-
2018
- 2018-01-16 MX MX2020010806A patent/MX2020010806A/es unknown
-
2019
- 2019-09-12 US US16/569,159 patent/US11253456B2/en active Active
-
2021
- 2021-04-21 AU AU2021202423A patent/AU2021202423A1/en active Pending
- 2021-10-22 JP JP2021173218A patent/JP7288026B2/ja active Active
-
2022
- 2022-01-13 US US17/574,865 patent/US11779531B2/en active Active
-
2023
- 2023-05-25 JP JP2023086030A patent/JP2023109950A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108348568A (zh) | 2018-07-31 |
| KR102576571B1 (ko) | 2023-09-11 |
| CA2992378A1 (en) | 2017-01-19 |
| ES2806989T3 (es) | 2021-02-19 |
| US11779531B2 (en) | 2023-10-10 |
| MX2020010806A (es) | 2020-10-28 |
| EP3747425A1 (en) | 2020-12-09 |
| CN114835784A (zh) | 2022-08-02 |
| JP2023109950A (ja) | 2023-08-08 |
| US20200060956A1 (en) | 2020-02-27 |
| AU2016293129A1 (en) | 2018-02-01 |
| EP3322430B1 (en) | 2020-03-25 |
| US10463591B2 (en) | 2019-11-05 |
| CN108348568B (zh) | 2021-12-28 |
| DK3322430T3 (da) | 2020-06-29 |
| WO2017009484A1 (en) | 2017-01-19 |
| US20190029939A1 (en) | 2019-01-31 |
| JP7288026B2 (ja) | 2023-06-06 |
| KR20230132623A (ko) | 2023-09-15 |
| KR102307260B1 (ko) | 2021-10-01 |
| AU2021202423A1 (en) | 2021-05-13 |
| US11253456B2 (en) | 2022-02-22 |
| AU2016293129B2 (en) | 2021-01-28 |
| JP2018523703A (ja) | 2018-08-23 |
| JP2022009415A (ja) | 2022-01-14 |
| EP3322430A1 (en) | 2018-05-23 |
| EP3954700A1 (en) | 2022-02-16 |
| US20220233425A1 (en) | 2022-07-28 |
| BR112018000660A2 (pt) | 2019-05-14 |
| KR20210120134A (ko) | 2021-10-06 |
| KR20180029237A (ko) | 2018-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| NZ596787A (en) | Growth hormone polypeptides and methods of making and using same | |
| JP2017512063A5 (es) | ||
| EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
| MY172997A (en) | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| JP2014224126A5 (es) | ||
| FI3677591T3 (fi) | Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b | |
| WO2013142859A3 (en) | Fusion proteins of superfolder green fluorescent protein and use thereof | |
| EA201100038A1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| EA201390820A1 (ru) | Слитый белок против рака | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| EP2403871A4 (en) | SPECIFIC ANTIBODIES AND EPITOPES OF A PRION PROTEIN | |
| NZ629843A (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| MX2011008759A (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| MX2020010716A (es) | Metodo para escindir de la fase solida peptidos unidos a una fase solida. | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
| IN2015DN03883A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |